Assays in new year
“strong visual lepidolite mineralisation encountered there in the first programme led to a decision to accelerate the stage 2 drilling”
this for me is not a strong statement for Spodumene, and perhaps setting market expectations
still, they can have a strong Lep resource, and Yahua must have leaned in for a reason.
the explicit desire to ‘re-rate’ the company is encouraging. Get to it fellas.
Ann: Chairman's Address to 2022 AGM, page-3
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add EFE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.001(12.5%) |
Mkt cap ! $5.588M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.5¢ | 0.4¢ | $868 | 215.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 4307256 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 5612206 | 16 |
View Market Depth
| Last trade - 15.40pm 15/10/2024 (20 minute delay) ? |
| EFE (ASX) Chart |